The reproductive toxicity of yttrium nitrate in a two-generation study in Sprague-Dawley rats

ObjectiveTo evaluate the effects of yttrium nitrate on the development of the parent, offspring and third generation of Sprague-Dawley (SD) rats by using a two-generation reproductive toxicity test.MethodsThe SD rats were randomly divided into 0 mg/kg group, 10.0 mg/kg group, 30.0 mg/kg group and 90.0 mg/kg group according to the different doses of yttrium nitrate administration. The reproductive toxicity of parent, offspring and third generation SD rats were compared.ResultsThe weight gains of F1a female rats and F2a female rats in the low-dose groups were significantly lower than those of the control groups (p < 0.05), the weight gains of F1a male rats in the medium-dose and high-dose groups were significantly lower than those of the control groups (p < 0.05), and the weight gains of F2a male rats in the low-dose, medium-dose and high-dose groups were significantly lower than those of the control groups (p < 0.05). In F0 male rats, the absolute weight and relative weight of the liver in the low-dose, middle-dose, and high-dose groups were significantly lower than those of the control group (p < 0.05). In F1b male rats, the absolute and relative weights of the liver in the medium-dose and high-dose groups were significantly lower than those of the control group (p < 0.05). In F2b male rats, the absolute and relative weights of the liver and spleen of the medium-dose and high-dose groups were significantly lower than those of the control group (p < 0.05). In F2a female rats, the absolute weight and relative weight of oviduct in the high-dose group were significantly lower than those in the control group (p < 0.05). The absolute and relative weights of lung, spleen, brain and uterus of F2b female rats in the high-dose group were higher than those of the control group (p < 0.05). But the pathological test results showed no hepatotoxicity. There was no statistically significant difference in sperm count and sperm motility between male rats in the yttrium nitrate administration groups and the control group (p > 0.05). There was no significant correlation between F0, F1a, F1b, F2a, F2b SD rats' reproductive organ lesions and the dose of yttrium nitrate.ConclusionYttrium nitrate at a dose of 90 mg/kg has no reproductive toxicity to two generations of SD rats, but 30.0 mg/kg dose of yttrium nitrate is toxic to the liver weight of male two generations of SD rats, but no hepatotoxicity.     

丁苯酞对颈动脉狭窄大鼠认知功能及海马CA1区神经元凋亡的影响及相关机制研究

摘要 目的：探讨与研究丁苯酞对颈动脉狭窄大鼠认知功能及海马CA1区神经元凋亡的影响及相关机制。方法：将颈动脉狭窄大鼠大鼠（n=42）随机为三组-模型组、低剂量丁苯酞（20 mg/kg）组和高剂量丁苯酞（40 mg/kg）组,每组14只。低剂量丁苯酞组与高剂量丁苯酞组每天给予20 mg/kg、40 mg/kg丁苯酞灌胃治疗,对照组给予等剂量的生理盐水灌胃,持续21 d。结果：低剂量丁苯酞组与高剂量丁苯酞组治疗第7 d、第14 d、第21 d的BBT评分低于模型组（P<0.05）,高剂量丁苯酞组低于低剂量丁苯酞组（P<0.05）。低剂量丁苯酞组与高剂量丁苯酞组治疗第21 d、第28 d的海马CA1区神经元凋亡指数低于模型组,高剂量丁苯酞组低于低剂量丁苯酞组（P<0.05）。低剂量丁苯酞组与高剂量丁苯酞组治疗第21 d、第28 d的脑组织超氧化物歧化酶（Superoxide dismutase,SOD）活性高于模型组（P<0.05）,丙二醛（Malondialdehyde,MDA）活性低于模型组（P<0.05）,高剂量丁苯酞组与低剂量丁苯酞组对比差异都有统计学意义（P<0.05）。低剂量丁苯酞组与高剂量丁苯酞组治疗第21 d、第28 d的海马CA1区BCL2-Associated X（Bax）、B淋巴细胞瘤-2（B-cell lymphoma-2,bcl-2）蛋白相对表达水平高于模型组（P<0.05）,高剂量丁苯酞组高于低剂量丁苯酞组（P<0.05）。结论：丁苯酞在颈动脉狭窄大鼠的应用能提高海马CA1区Bax、Bcl-2蛋白的表达,抑制神经元的凋亡,改善氧化应激状态,从而提高大鼠的认知功能。     

虫草素对慢性肾脏病大鼠血管内皮损伤的保护作用及其机制

摘要 目的：探讨虫草素对慢性肾脏病(chronic kidney disease,CKD)大鼠血管内皮损伤的保护作用及其机制。方法：慢性肾脏病大鼠(n=48)随机平分为四组-模型组、虫草素高剂量组、虫草素中剂量组、虫草素低剂量组,虫草素高剂量组、虫草素中剂量组、虫草素低剂量组,分别给予虫草素160 mg/kg、80 mg/kg、40 mg/kg,模型组灌胃给予等量生理盐水,每天1次,连续给药治疗2周。结果：虫草素高剂量组、虫草素中剂量组、虫草素低剂量组治疗1周、治疗2周的24 h尿量、血清尿素氮(blood urea nitrogen,BUN)与肌酐(serum creatinine,Scr)水平都低于模型组(P<0.05),体重都高于模型组(P<0.05),不同剂量组别之间对比差异也有统计学意义(P<0.05)。虫草素高剂量组、虫草素中剂量组、虫草素低剂量组治疗2周的结缔组织生长因子(Connective tissue growth factor,CTGF)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)蛋白相对表达水平高于模型组(P<0.05),肾小球硬化指数、肾小管损伤评分都低于模型组(P<0.05),不同剂量组别之间对比差异也有统计学意义(P<0.05)。结论：虫草素在慢性肾脏病大鼠的应用能发挥血管内皮损伤保护作用,促进改善大鼠的肾功能,提高大鼠的体重,且具有剂量依赖性。     

长期低剂量摄入烯草酮原药对大鼠的毒性作用

目的研究长期低剂量摄入烯草酮原药对大鼠的毒性作用,确定其最大无作用剂量,为安全生产及慢性毒性实验提供剂量参考。方法将80只SD大鼠（雌雄各半）按体重随机分为4组,分别为烯草酮原药14.9mg/kg.d体重组、89.6 mg/kg.d体重组、537.5 mg/kg.d体重和正常对照组。在实验结束后处死实验大鼠,同时检测血液学、血清生化、体重和脏器系数等指标,并对结果进行统计学处理。结果与结论烯草酮原药对雄、雌性大鼠经口染毒剂量为89.6 mg/kg.d体重及以上时,对大鼠有毒性效应;长期低剂量摄入烯草酮原药对大鼠最大无作用剂量为14.9 mg/kg.d体重。     

Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits

BACKGROUND: The developmental toxicity potential of vorinostat (suberoylanilide hydroxamic acid [SAHA], ZOLINZA), a potent inhibitor of histone deacetylase (HDAC), was assessed in Sprague-Dawley rats and Dutch Belted rabbits. HDAC inhibitors have been shown to mediate the regulation of gene expression, induce cell growth, cell differentiation, and apoptosis of tumor cells. Range-finding studies established oral dose levels of 5, 15, or 50 mg/kg/day and 20, 50, or 150 mg/kg/day in rats and rabbits, respectively. METHODS: Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively. Separate studies evaluated toxicokinetic parameters at the mid- and high-dose levels. RESULTS: There was no maternal toxicity observed at the highest dose levels; however, hematology and serum biochemistry changes were characterized in the range-finding studies. Vorinostat did not induce morphological malformations in either rat or rabbit fetuses. In rats, drug-related developmental toxicity was observed only in the high-dose group and consisted of markedly decreased fetal weight and increases in fetuses with a limited number of skeletal variations. In rabbits, drug-related developmental toxicity was also observed only in the high-dose group and consisted of slightly decreased fetal weight and increases in fetuses with a short 13th rib and incomplete ossification of metacarpals. Maternal exposures to vorinostat based on AUC and Cmax values were comparable at the high-dose levels of both species. Rabbits tolerated higher dosages probably due to more extensive metabolism. Maternal concentrations of vorinostat were approximately 1,000-fold above the known in vitro HDAC inhibitory concentration. CONCLUSIONS: Review of previous work with valproic acid, another HDAC inhibitor, suggest that the developmental toxicity profiles of these 2 compounds are not the result of HDAC inhibition but involve other mechanisms.     

Developmental toxicity and uterotrophic studies with di-2-ethylhexyl terephthalate

BACKGROUND: These studies were conducted to evaluate the potential adverse effects of di-2-ethylhexyl terephthalate (DEHT) exposure on in utero development in mice and rats. In addition, a uterotrophic assay for estrogenic activity was conducted in sexually immature rats. METHODS: In the developmental toxicity studies, diet containing DEHT was fed to four groups of mated female Crl:CD(SD)IGS BR rats (25/group) from gestation day (GD) 0-20 or Crl:CD1(ICR) mice (25/group) from GD 0-18. Concentrations within the feed were 0, 0.3, 0.6, and 1.0% for the rats and 0, 0.1, 0.3, and 0.7% for the mice. Laparohysterectomies were carried out on the last day of exposure and the numbers of fetuses, early and late resorptions, total implantations, and corpora lutea were recorded. The fetuses were weighed, sexed, and examined for external, visceral and skeletal malformations, and developmental variations. The dose rate from dietary DEHT exposure was 0, 226, 458, and 747 mg/kg/day in the rats and 197, 592, and 1382 mg/kg/day in the mice for the control, low, mid, and high-exposure groups, respectively. RESULTS: DEHT exposure did not affect clinical observations. A slight reduction in body weight gain was noted in the high-dose level rat group; the remaining groups were unaffected. At necropsy, increased liver weights were noted in the high-dose rat group and the mid- and high-dose mouse groups. Mean numbers of implantation sites and viable fetuses, mean fetal weights, and mean litter proportions of preimplantation loss, early resorptions, late resorptions, and fetal sex ratios were unaffected by DEHT exposures. No test article-related malformations or variations were observed at any concentration level in the rat and mouse developmental toxicity studies. In the uterotrophic assay for estrogenic activity, sexually immature female rats received oral gavage doses 20, 200, or 2000 mg DEHT/kg bw/day from postnatal day (PND) 19-21. A slight reduction in rate of body weight gain was noted on the first day of dosing in the high dose group, but no other indications of toxicity were evident. DEHT exposure did not affect wet or blotted uterine weight parameters in any of these dose groups. The NOEL for developmental toxicity in rats was 747 mg/kg/day and 1382 mg/kg/day in mice. The NOEL for estrogenic activity was 2000 mg/kg/day. The NOEL for maternal toxicity was 458 mg/kg/day in rats and 197 mg/kg/day in mice. CONCLUSIONS: The lack of adverse developmental effects with DEHT exposure are in contrast to the adverse developmental effects noted after di-2-ethylhexyl phthalate (DEHP) exposure. The difference between the effects noted with the ortho-constituent (DEHP) and the lack of effects reported with the para-constituent (DEHT) is due most likely to differences in metabolism and the formation of the stable monoester, mono-2-ethylhexyl phthalate (MEHP) from the DEHP moiety.     

苦参碱对大鼠乳腺癌细胞荷瘤生长及其炎性因子与免疫功能的影响

目的：探讨苦参碱对大鼠乳腺癌细胞荷瘤大鼠生长及其炎性因子与免疫功能的影响。方法：雌性Wistar大鼠60只,随机分为对照组（n=10）,乳腺癌细胞荷瘤大鼠建模组（n=50）。建模大鼠再随机分为5组（n=10）：模型组、苦参碱低（50 mg/kg）、中（100 mg/kg）、高（200 mg/kg）剂量组和香菇多糖（200 mg/kg）组。除对照组外,每只大鼠右腋皮下接种0.4 ml Walker 256乳腺癌细胞悬液（5×10⁷ cells/ml）。按10 ml/kg的体积腹腔注射给药,2次/日,连续14 d。14 d后麻醉大鼠,腹主动脉取血,取瘤组织称取质量,计算抑瘤率;检测大鼠外周血IL-2、IFN-γ、IL-6、IL-10、TGF-β、CD3⁺、CD4⁺、CD8⁺、IgG、IgM、IgA水平。结果：苦参碱低、中、高剂量组和香菇多糖组大鼠瘤块平均质量分别为（4.99±0.93）g、（4.52±0.92）g、（4.22±1.18）g、（4.52±0.92）g,与模型组（6.62±1.20）g比较均明显降低（P<0.01）。苦参碱各剂量组与香菇多糖组比较,瘤块平均质量无明显差异（P>0.05）。苦参碱低、中、高剂量组和香菇多糖组抑瘤率分别为24.6%、31.7%、36.3%和27.9%,组间无统计学差异。模型组大鼠IL-2、IFN-γ、CD8⁺较对照组明显降低（P<0.01）;而IL-6、IL-10、TGF-β、CD3⁺、CD4⁺、IgG、IgM、IgA较对照组明显升高（P<0.01）。苦参碱低、中、高剂量组和香菇多糖组IL-2、IFN-γ、CD8+较模型组显著升高（P<0.01,P<0.05）;而IL-6、IL-10、TGF-β、CD3⁺、CD4⁺、IgG、IgM、IgA较模型组明显降低（P<0.01,P<0.05）。与香菇多糖组比较,苦参碱低、中剂量组IgM、IgA明显升高（P<0.01,P<0.05）;高剂量组IL-2和IFN-γ、IgA水平明显升高（P<0.01,P<0.05）;低剂量组IFN-γ水平明显降低（P<0.05）;高剂量组IL-10、CD4⁺水平明显降低（P<0.01,P<0.05）。结论：苦参碱具有明显的抑制肿瘤生长的作用,其抑瘤机制与其提高细胞和体液免疫、减轻炎症反应有关。     

Acute toxicity study of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol, and γ-tocopherol in rats

Liposomes have been used for the delivery of antioxidants to different tissues and organs for the treatment of oxidative stress-induced injuries. In this study, the acute toxicity of a single dose of intravenously (i.v.) administered liposomal antioxidant formulation, containing N-acetylcysteine (NAC) with or without α-tocopherol (α-T) or γ-tocopherol (γ-T), in rats was examined. Each group consisted of 5 male and 5 female Sprague-Dawley rats, with a control group receiving empty dipalmitoylphosphatidylcholine (DPPC) liposomes (660 mg/kg) and test groups receiving DPPC liposomes (660 mg/kg) entrapped with 1) NAC (200 mg/kg), 2) NAC (200 mg/kg) and α-T (83.3 mg/kg), and 3) NAC (200 mg/kg) and γ-T (71.4 mg/kg). These dose levels were determined from the dose-range-finding study and were considered to be the maximum feasible dose (MFD) levels, based on the volume of 10 mL/kg and physical properties and viscosity of the test articles that could be safely administered to rats by an i.v. injection. Two weeks after treatment (day 15), rats in the control group and three test groups exhibited no clinical signs of toxicity during the dosing period or during the 14-day post-treatment period. Weight gain and food consumption in all animals was appropriate for the age and sex of animals. Clinical pathology findings (e.g., hematology, coagulation, clinical chemistry, and urinalysis) were unremarkable in all rats and in all groups. In conclusion, the results of this study showed no treatment-related toxicity in rats at the MFD level by a single bolus i.v. administration.     

Effects of Exogenous Selenium on Nicotine-Induced Oxidative Stress in Rats

The effect of two different doses of selenium [1 and 50 μg selenium/100 g body weight (wt)] on nicotine-induced oxidative damage in liver was investigated in experimental rats. Male albino rats were maintained for 60 days as follows: (1) control group (normal diet), (2) nicotine group (0.6 mg/kg body wt)/day, (3) high-dose selenium (50 μg/100 g body wt)/day, (4) high-dose selenium (50 μg/100 g body wt) + nicotine (0.6 mg/kg body wt)/day, (5) low-dose selenium (1 μg/100 g body wt)/day, and (6) low-dose selenium (1 μg/100 g body wt) + nicotine (0.6 mg/kg body wt)/day. Nicotine administration caused a decrease in the activity of antioxidant enzymes, an increase in the concentration of lipid peroxidation products and protein carbonyls and an increase in the activity of nitric oxide synthase compared to the control group. Coadministration of nicotine and selenium reduced the concentration of lipid peroxidation products and increased the activity of antioxidant enzymes compared to the nicotine group. Selenium also enhanced the metabolism of nicotine. The antioxidant effect was more significant in the group administered a low dose of selenium.     

阿霉素注射剂量对肾病综合征大鼠脂蛋白脂酶和卵磷脂胆固醇酰基转移酶水平的影响

摘要 目的：探讨阿霉素注射剂量对肾病综合征（nehpmtic syndrome,NS）大鼠脂蛋白脂酶和卵磷脂胆固醇酰基转移酶（Leci-thin cholesterol acyltransferase,LCAT）水平的影响。方法：64只SD大鼠随机平分为四组-对照组、小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组,四组大鼠经尾静脉一次性注射阿霉素0 mg/kg、2 mg/kg、4 mg/kg、8 mg/kg,检测造模后不同时间点大鼠肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶水平变化情况。结果：小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组造模后7 d、14 d、21 d的体重与每日采食量、血肌酐与尿素氮都低于对照组（P<0.05）,24 h尿蛋白高于对照组（P<0.05）,且存在剂量依赖性,三组间对比差异有统计学意义（P<0.05）。小剂量阿霉素组、中剂量阿霉素组与高剂量阿霉素组造模后21 d、28 d的肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶相对表达水平低于对照组（P<0.05）,且存在剂量依赖性,三组间对比差异有统计学意义（P<0.05）。结论：小剂量阿霉素可抑制大鼠肾脏脂蛋白脂酶和卵磷脂胆固醇酰基转移酶的表达,能快速有效建立肾病综合征大鼠模型,具有很好的模拟造模效果。     

Cocktail探针药物法评价傣药"雅解沙把" 对大鼠肝药酶P450亚型 CYP1A2、CYP2C19、CYP2E1、CYP3A4 活性的影响

目的:采用cocktail探针药物法研究傣药"雅解沙把"对肝细胞色素P450亚型CYP1A2、CYP2C19、CYP2E1、CYP3A4的影响。方法:将SD大鼠随机分为空白对照组、苯巴比妥钠组(10.8 mg/kg)、"雅解沙把"低剂量组(0.27 g生药/kg)和"雅解沙把"高剂量组(2.43 g生药/kg),按上述剂量灌胃给药,空白对照组灌胃蒸馏水。连续灌胃7天后处死动物,取肝脏制备肝微粒体,以甲硝唑为内标,建立HPLC方法检测Cocktail探针药物奥美拉唑、氯唑沙宗、咖啡因、氨苯砜的代谢情况。结果:与空白对照组比较,"雅解沙把"低剂量组和高剂量组氯唑沙宗的代谢明显升高,氯唑沙宗的含量显著降低(P0.01),"雅解沙把"高剂量组奥美拉唑和氨苯砜的代谢明显升高,奥美拉唑和氨苯砜的含量明显降低(P0.05)。"雅解沙把"低剂量组和高剂量组虽咖啡因代谢较与空白对照组有上升的趋势,但差异无统计学意义(P0.05)。结论:傣药"雅解沙把"能促进肝药酶CYP3A4、CYP2C19、CYP2E1的活性,加速药物代谢,这可能是其解药物毒的作用机制之一。     

Developmental Toxicity Studies with Atrazine and its Major Metabolites in Rats and Rabbits

Atrazine (ATR), hydroxyatrazine (OH‐ATR), and the three chloro metabolites of ATR (deethylatrazine [DEA], deisopropylatrazine [DIA], diaminochlorotriazine [DACT]) were evaluated for developmental effects in rats and rabbits. Three developmental toxicity studies were conducted on ATR in rats (two studies) and rabbits and a developmental toxicity study was conducted in rats for each of the four ATR metabolites DEA, DIA, DACT, and OH‐ATZ. ATR administration by gavage to pregnant rats and rabbits from implantation (gestation day [GD] 6 in rat, GD 7 in rabbit) through closure of the palate (GD 15 in rat and GD 19 in rabbit) did not statistically significantly alter the incidence of developmental abnormalities or malformations at dose levels up to 100 (rat) or 75 (rabbit) mg/kg bw/day. There were no effects on developmental toxicity parameters for DEA, DIA, DACT, or OH‐ATR at oral dose levels up to 100, 100, 150, or 125 mg/kg bw/day, respectively, with the exception of reductions in fetal body weight by DACT and OH‐ATR in the presence of decreased maternal body weight gain. ATR did not adversely affect developmental end points in a two‐generation study conducted in rats exposed to dose levels up to 500 ppm (38.7 mg/kg/day) in the diet. The 500‐ppm dose level resulted in significantly reduced maternal body weight gain. Overall, data show that neither ATR nor its metabolites statistically significantly affected rat or rabbit embryo‐fetal development even at dose levels producing maternal toxicity.     

茅莓对大鼠非细菌性前列腺炎的影响

采用角叉菜胶和消痔灵制备大鼠非细菌性前列腺炎病理模型,研究茅莓提取物对大鼠非细菌性前列腺炎的影响。取前列腺炎模型大鼠随机分为模型对照组、茅莓水提物高(5.0 g/kg)、低剂量组(2.5 g/kg)、茅莓醇提物高(5.0 g/kg)、低剂量组(2.5 g/kg),各组灌胃给药每天2次,连续28 d,观察大鼠前列腺湿重、指数及病理组织检查等指标的变化。结果表明:茅莓能抑制前列腺炎模型大鼠前列腺腺体增重(P<0.05),减轻炎性细胞浸润和损伤(P<0.05),对大鼠非细菌性前列腺炎有一定的治疗作用。     

Neonatal exposure of ketamine inhibited the induction of hippocampal long-term potentiation without impairing the spatial memory of adult rats

Ketamine is one of general anesthetics and has been commonly used in obstetric and pediatric anesthesia. However, effects of exposure to ketamine on neonatal brain are largely unknown. In this study, we aim to investigate the effect of neonatal exposure of ketamine on spatial memory and long-term potentiation (LTP) in the hippocampus of adult rats. One-week-old neonatal rats were separated into ketamine group and control group. Neonatal rats in ketamine group were received intraperitoneal injection of 25 mg/kg (low-dose group, N = 8) or 50 mg/kg ketamine (high-dose group, N = 8). Neonatal Rats in control group received saline injection (N = 8). After 10 weeks, the spatial memory of adult rats was examined by using Morris Water Maze, and LTP in the hippocampus of adult rats was assessed by electrophysiological experiment. We found that exposure of ketamine to neonatal rats, either low-dose or high-dose, had not induced alteration on their adulthood’s escape latency, swimming speed and the percentage of time spent in original quadrant compared with the control. The electrophysiological examination showed that the induction of LTP in hippocampus was significantly reduced in adult rats of ketamine group (either low-dose or high-dose). Our study showed that neonatal exposure of ketamine inhibited the induction of hippocampal LTP without impairing the spatial memory of adult rats.     

Developmental toxicity evaluation of butylparaben in Sprague-Dawley rats

The developmental toxicity potential of butylparaben (CAS No. 94-26-8) was evaluated in rats. Sprague-Dawley rats were administered butylparaben in 0.5% carboxymethylcellulose by oral gavage at dose levels of 0, 10, 100, or 1,000 mg/kg/day on gestation days (GD) 6-19 (sperm positive day = GD 0). Caesarean sections were performed on GD 20 and fetuses were evaluated for viability, growth, and external, visceral, and skeletal abnormalities. Each group consisted of 25 females, with at least 21 per group being pregnant. The highest dose level caused decreases in maternal weight gain during some of the measurement intervals and was statistically significant during the GD 18-20 interval. Maternal food consumption was significantly decreased in the highest dose group over the dosing period (GD 6-20). There were no differences from control in any of the developmental parameters measured, including embryo/fetal viability, fetal weight, malformations, or variations. Based on the results of this study, the maternal NOAEL for butylparaben was 100 mg/kg/day. Butylparaben does not have the potential to cause developmental toxicity in the Sprague-Dawley rat at oral dosages up to 1000 mg/kg/day.     

有机磷阻燃剂TDCIPP对雌性大鼠甲状腺的潜在毒性作用

目的: 研究磷酸三(1, 3-二氯-2-丙基)酯(TDCIPP)对雌性大鼠甲状腺系统的潜在毒性作用及机制。方法: 将32只离乳3周的雌性SD大鼠随机分为对照组(玉米油灌胃)及TDCIPP低、中、高剂量组(50、100、250 mg/kg·d,溶于玉米油)(n=8),灌胃给药21 d,每天1次。于末次给药后处死动物,取血和甲状腺、肝脏,检测血清中促甲状腺激素(TSH)、三碘甲腺原氨酸(T3), 甲状腺素(T4)和游离甲状腺素(FT4)水平变化;组织切片(HE染色)用于检测甲状腺形态学病变;RT-PCR技术与Western blot技术检测与甲状腺功能相关的基因和蛋白表达的变化。结果: 与对照组比较,TDCIPP染毒后大鼠甲状腺出现滤泡排列不规则、胶质变少、滤泡增生、肥大等现象,TDCIPP低剂量组的血清TSH水平和高剂量组的T3水平均显著升高(P＜0.05),低剂量组促甲状腺激素受体(TSHR)mRNA表达和中、高剂量组甲状腺激素受体β(TRβ)蛋白表达均显著降低(P＜0.05,P＜0.01),中、高剂量组甲状腺过氧化物酶(TPO)mRNA表达显著增高(P＜0.05,P＜0.01),三个剂量组尿苷二磷酸葡萄糖醛酸转移酶(UGTs)、细胞色素氧化酶-3A1(CYP3A1)蛋白表达水平显著上调(P＜0.05)。结论: 大鼠暴露在50 mg/(kg·d)以上剂量的TDCIPP,即可以刺激甲状腺组织的增生,改变血清中甲状腺素的水平,干扰甲状腺的功能,表现出对甲状腺的毒性作用。     

Ameltolide. I: Developmental toxicology studies of a novel anticonvulsant

Ameltolide, a novel anticonvulsant agent, has been shown in animal models to be effective in controlling seizures. The developmental toxicity of ameltolide was evaluated in two species. Naturally mated rats and rabbits were dosed once daily by gavage on gestation days (GD) 6-17 and 6-18, respectively. Rats were given doses of 0, 10, 25, or 50 mg/kg; rabbits were given 0, 25, 50, or 100 mg/kg. Laparotomy was performed on rats on GD 20 and on rabbits on GD 28. In rats, maternal toxicity was indicated at the 25- and 50-mg/kg dose levels by depressed body weight gain. Fetal body weight was depressed at the 50-mg/kg dose level. Fetal viability and morphology were not affected. The no-observed effect levels (NOEL) for adult and developmental toxicity in the rat were 10 and 25 mg/kg, respectively. In rabbits, maternal toxicity was indicated by a net loss in body weight at the 50- and 100-mg/kg dose levels. Fetal viability and body weight were depressed at the 100 mg/kg dose level. Shortened digits occurred on the right forepaw of one fetus at the 50-mg/kg dose level (in conjunction with severe maternal toxicity) and on the hindpaws of two fetuses from separate litters at the 100-mg/kg dose level. Incomplete ossification of the phalanges occurred on the forepaws of nine fetuses from four litters at the 100-mg/kg dose level. Ameltolide was weakly teratogenic in the rabbit. The NOEL for adult and developmental toxicity in the rabbit was 25 mg/kg.     

Developmental toxicity evaluation of sodium thioglycolate administered topically to Sprague-Dawley (CD) rats and New Zealand White rabbits

BACKGROUND: Sodium thioglycolate, which has widespread occupational and consumer exposure to women from cosmetics and hair‐care products, was evaluated for developmental toxicity by topical exposure during the embryonic and fetal periods of pregnancy METHODS: Timed‐mated Sprague–Dawley rats (25/group) and New Zealand White (NZW) rabbits (24/group) were exposed to sodium thioglycolate in vehicle (95% ethanol:distilled water, 1:1) by unoccluded topical application on gestational days (GD) 6–19 (rats) or 6–29 (rabbits) for 6 hr/day, at 0, 50, 100, or 200 mg/kg body weight/day (rats) and 0, 10, 15, 25, or 65 mg/kg/day (rabbits). At termination (GD 20 rats; GD 30 rabbits), fetuses were examined for external, visceral, and skeletal malformations and variations. RESULTS: In rats, maternal topical exposure to sodium thioglycolate, at 200 mg/kg/day (the highest dose tested) on GD 6–19, resulted in maternal toxicity, including reduced body weights and weight gain, increased relative water consumption and one death. Treatment‐related increases in feed consumption and changes at the application site occurred at all doses, in the absence of increased body weights or body weight change. Fetal body weights/litter were decreased at 200 mg/kg/day, with no other embryo/fetal toxicity and no treatment‐related teratogenicity in any group. In rabbits, maternal topical exposure to sodium thioglycolate on GD 6–29 resulted in maternal dose‐related toxicity at the dosing site in all groups; no maternal systemic toxicity, embryo/fetal toxicity, or treatment‐related teratogenicity were observed in any group. CONCLUSIONS: A no observed adverse effect level (NOAEL) was not identified for maternal toxicity in either species with the dosages tested. The developmental toxicity NOAEL was 100 mg/kg/day (rats) and ≥65 mg/kg/day (rabbits; the highest dose tested). The clinical relevance of theses study results is uncertain because no data were available for levels, frequency, or duration of exposures in female workers or end users. Birth Defects Research Part B 68:144–161, 2003. © 2003 Wiley‐Liss, Inc.     

Prevention Effects and Possible Molecular Mechanism of Mulberry Leaf Extract and its Formulation on Rats with Insulin-Insensitivity

For centuries, mulberry leaf has been used in traditional Chinese medicine for the treatment of diabetes. This study aims to test the prevention effects of a proprietary mulberry leaf extract (MLE) and a formula consisting of MLE, fenugreek seed extract, and cinnamon cassia extract (MLEF) on insulin resistance development in animals. MLE was refined to contain 5% 1-deoxynojirimycin by weight. MLEF was formulated by mixing MLE with cinnamon cassia extract and fenugreek seed extract at a 6:5:3 ratio (by weight). First, the acute toxicity effects of MLE on ICR mice were examined at 5 g/kg BW dose. Second, two groups of normal rats were administrated with water or 150 mg/kg BW MLE per day for 29 days to evaluate MLE’s effect on normal animals. Third, to examine the effects of MLE and MLEF on model animals, sixty SD rats were divided into five groups, namely, (1) normal, (2) model, (3) high-dose MLE (75 mg/kg BW) treatment; (4) low-dose MLE (15 mg/kg BW) treatment; and (5) MLEF (35 mg/kg BW) treatment. On the second week, rats in groups (2)-(5) were switched to high-energy diet for three weeks. Afterward, the rats were injected (ip) with a single dose of 105 mg/kg BW alloxan. After four more days, fasting blood glucose, post-prandial blood glucose, serum insulin, cholesterol, and triglyceride levels were measured. Last, liver lysates from animals were screened with 650 antibodies for changes in the expression or phosphorylation levels of signaling proteins. The results were further validated by Western blot analysis. We found that the maximum tolerance dose of MLE was greater than 5 g/kg in mice. The MLE at a 150 mg/kg BW dose showed no effect on fast blood glucose levels in normal rats. The MLE at a 75 mg/kg BW dose and MLEF at a 35 mg/kg BW dose, significantly (p < 0.05) reduced fast blood glucose levels in rats with impaired glucose and lipid metabolism. In total, 34 proteins with significant changes in expression and phosphorylation levels were identified. The changes of JNK, IRS1, and PDK1 were confirmed by western blot analysis. In conclusion, this study demonstrated the potential protective effects of MLE and MLEF against hyperglycemia induced by high-energy diet and toxic chemicals in rats for the first time. The most likely mechanism is the promotion of IRS1 phosphorylation, which leads to insulin sensitivity restoration.     

Toxicity profiling of the ethanolic extract of Citrullus lanatus seed in rats: behavioral,biochemical and histopathological aspects

Citrullus lanatus (Cucurbitaceae) is conventionally used for the treatment of urinary tract infection, renal stones, hypertension, diabetes and diarrhoea. Current study evaluates acute and 28 days repeated toxicity ethanolic extract of C. lanatus seed (EECLS) in Wistar rats to measure its safety profile. The single dose (2000 mg/kg BW) of EECLS was administered while in 28 days repeated study 250, 500 and 1000 mg/kg BW were administered orally in rats. Parameters such as biochemical, haematological and histopathological were analysed in subacute toxicity study. During study, no apparent sign of toxicity, behavioural changes and mortality were detected in acutely exposed animals. In 28 days repeated toxicity study, rats did not show significant changes in behaviour, gross pathology, body weight, biochemical and haematological parameters. Abridged serum glucose and cholesterol levels during the study designate their roles in treatment of hyperglycaemic and hyperlipidaemic conditions. No significant difference was observed in histopathology of liver and kidneys of treated rats. The current investigation demonstrated that EECLS is non-toxic below 1000 mg/kg BW and provides protection to some body organs. The data propose that LD₅₀ of EECLS was greater than 2000 mg/kg BW and the no observed adverse effect level (NOAEL) of EECLS was at the dose of 1000 mg/kg in rats. Taken together, our finding suggests that, EECLS is safe and provides some protection to body organs; also, its extract can be used for further preclinical and clinical evaluation for its therapeutic activity.